Cannabis stocks faced a precarious summer last year, but one analyst has noted that “equity markets (are) rebounding,” causing an upswing across the sector — including in Australia.
In a note sent to investors on January 22, Cameron Bell, an analyst with boutique bank Canaccord Genuity Australia, said investor confidence in the Australian cannabis market has been renewed due to an exceptionally strong recent performance from the global cannabis space.
Canaccord’s own Australian Cannabis Index has risen 34 percent over the last month, Bell said, bouncing back from the hit of over 50 percent that it took in 2019.
Introducing Our NEW Gold Outlook Report
BURSTING With Exclusive Information Not Found Anywhere Else. Don't Get Left Behind!
Grab Your FREE Gold Report Today!
“The strength has been partially led by investor sentiment in offshore markets, as some key concerns have eased while expectations for demand growth remain very high and access to funding improves.”
Bell also attributed more reasonable valuations as an aid to rising share prices.
Some of the largest companies on Canaccord’s index by market cap, including EcoFibre (ASX:EOF), Elixinol Global (ASX:EXL,OTC Pink:ELLXF) and Cann Group (ASX:CAN,OTC Pink:CNGGF), have seen impressive growth in the last month.
EcoFibre is up almost 10 percent in the last month, while Elixinol and Cann Group have soared 68.9 percent and 114.7 percent, respectively, in the same span of time.
Meanwhile, Bell said patient applications through the Therapeutics Goods Association’s (TGA) Special Access Scheme-B (SAS-B) pathway were on the rise in December.
Approvals for patients increased to 3,685 application authorizations that month, up 8 percent from the 3,404 confirmations in November.
December’s numbers are also almost seven times larger year-over-year than the 490 approvals issued in December 2018, indicating a rapid rise in patient adoption for these items.
By the end of 2019, the TGA had approved over 28,000 patients throughout the year. This figure exceeded Canaccord’s expectation of 25,000 approvals, reported in a previous Australian cannabis update released in November.
Ninety percent of total SAS-B approvals have happened in the last year, Bell noted.
If growth continues at the current rate, the total number of approvals is expected to grow to 72,000 by the end of calendar 2020.
The analyst noted that there’s been an interesting shift away from the Authorised Prescribers path, which gives medical practitioners in Australia the ability to prescribe unapproved therapeutic goods, like cannabis, directly to eligible patients.
According to the TGA, there were 22 authorised prescribers in Australia at the end of December, a steep drop from the 60 reported at the end of July, Bell wrote.
Don’t forget to follow us @INN_Australia for real-time news updates!
Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.
Company is strategically building a diverse edibles portfolio with taste-forward and effects-driven products to cater to market and consumer needs
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced the launch of Wonder Wellness (“Wonder”) Gummies and availability in Illinois. The new low-dose edibles are enhanced with botanicals to complement the overall cannabis experience, and their simple packaging communicates desired effects so wellness-minded category newcomers can consume with confidence to add cannabis as a part of their daily lifestyles.
Reports Eighth Consecutive Quarter of Positive Adjusted EBITDA and Positive Adjusted EBITDA from Cannabis Business
Aphria Inc. (” Aphria ,” ” we ,” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis-lifestyle consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today reported its financial results for the third quarter and nine months ended February 28, 2021 . All amounts are expressed in Canadian dollars, unless otherwise noted and except for per gram, kilogram, kilogram equivalents, and per share amounts.
Thoughtful Brands, Inc. (CSE:TBI)(FWB:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands“), an eCommerce technology company that researches, develops, markets, and distributes natural health products through various brands in North America and Europe, announces that it intends to consolidate its issued and outstanding common shares (“Shares”) at a ratio of ten (10) pre-consolidated Shares to one (1) post-consolidation Share (the “Consolidation
The Company currently has 389,274,701 Shares issued and outstanding. Following the Consolidation there will be approximately 38,927,470 Shares issued and outstanding. No fractional Shares will be issued and any fractions of a Share will be rounded down to the nearest whole number of Shares. The exercise or conversion price and the number of Shares issuable under any of the Company’s outstanding convertible securities will be proportionately adjusted upon Consolidation.
In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.
Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.
The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement
Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination